Hikari Power’s Lineage Cell Therapeutics LCTX Stock Holding History

Hikari Power’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-40,318	Closed	-$122K	–	99
2017 Q1	$122K	Buy	+40,318	New	+$114K	0.02%	67

Other funds holding LCTX

Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PGP

Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

MHP

Manatuck Hill Partners Westport, Connecticut $302M AUM 117.41% 1-Year Est. Return

DWM

Destination Wealth Management Walnut Creek, California $4.28B AUM 19.27% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Hikari Power's LCTX Position: Q2 2017 in Review

Hikari Power sold out of Lineage Cell Therapeutics (LCTX) in Q2 2017, closing a stake of 40,318 shares — an estimated $122K sold.

Hikari Power first reported a position in LCTX in Q1 2017 and held it in 1 quarter. The position peaked at $122K in Q1 2017. 109 funds tracked by Wall St. Rank hold LCTX as of Q2 2017.

Hikari Power reported no remaining Lineage Cell Therapeutics position as of Q2 2017 after selling out during the quarter.
Hikari Power sold 40,318 Lineage Cell Therapeutics shares in Q2 2017, an estimated $122K.
Hikari Power first reported a position in Lineage Cell Therapeutics in Q1 2017 and held it in 1 quarter.
Hikari Power's Lineage Cell Therapeutics position peaked at $122K in Q1 2017.
109 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2017.

Based on Hikari Power's 13F filing for Q2 2017, filed 9 Aug 2017.